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Cough is frequently encountered in clinical practice.  Benzonatate 
is the only non-narcotic cough suppressant available for 
treatment of persistent cough.  Symptoms of benzonatate toxicity 
can range from benign to life threatening, and treatment can 
prove to be a challenge given the lack of a specific antidote. 
Table 1. Side Effects and Doses
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Figure 1. Presenting EKG.
Case
 •  A 17 year-old female was brought to the ED after admitting 
purposeful ingestion of twelve 200mg benzonatate capsules to 
her father.    
 •  Upon arrival the patient was unresponsive with cardiac 
monitoring showing ventricular fibrillation.  Return of 
spontaneous circulation was achieved per ACLS protocol.  
 •  She was then treated with therapeutic hypothermia for 24 
hours, bicarbonate infusions and intravenous lipids.  
 •  Presenting EKG demonstrated a markedly prolonged QTc 
interval of 634. (Figure 1)  
 •  Within 48 hours of arrival, the patient was successfully warmed 
and extubated with only mild retrograde amnesia as a residual 
deficit.
•  Benzonatate achieves its desired effect of cough suppression by means of anesthetizing stretch receptors in the lungs and neighboring tissues.  Molecularly, it functions as a 
sodium channel blocker, similar to procaine and tetracaine.  (Figures 2 and 3)   
•  The toxicity margin has been reported as ranging broadly from as little as 200mg to upwards of 3600mg.  (Table 1)
•  Toxicity can manifest as tachycardia, agitation, seizures, coma, ventricular dysrhythmia, cardiac arrest, hypotension, and asystole.  These symptoms have been reported to 
present within 15 minutes of ingestion.  (Table 2)  
•  Therapeutic hypothermia can be indicated for unresponsive patients who survive VT/VF arrests.   
•  Benzonatate toxicity can cause profound metabolic acidosis, at times requiring bicarbonate infusions to maintain physiologic pH’s.  
•  Intravenous lipid infusions can help bind the benzonatate molecule before it can seed tissues, thereby minimizing its duration of toxicity.  
•  The number of benzonatate prescriptions increased by 54% from 2004-2009, with 63% of  those prescriptions coming from primary physicians.  The low toxicity margin and 
rapidity of onset of toxicity suggests that more restraint and careful consideration should be exercised when prescribing benzonatate, especially in light of its potentially lethal 
side effect profile.  (Figure 4)













Table 2. Selected Side Effects
Moderate and Major 
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